Positioning political selling, disclosed 2026-09-17
Options put/call open interest 0.73, read 2026-11-02
Ethical passes the values gate
Price194.31 USD
Fair value142.63
Ethical score87.4/100
Value readOvervaluedas of 2 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup139.69+39.1% to today ✓Distribution gives way to Markup after an 8% rise in 4 weeks
2026-09-10Read Distribution128.89+50.8% to today Markup gives way to Distribution after a 6% slide in 10 weeks
2026-07-02Read Markup137.00+41.8% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
PTC Inc. holds its Markup at $194.31. The statistical read favours the buyers, held for 19 days.
As held on the ledger · 2026-11-02
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 19 days
Price at the screen
$194.31
Valuation
18.97 trailing · 21.93 forward price to earnings
Values screen
PASS· score 87.4
Beta
1.00
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
20.70%
Below 33%
Interest-bearing debt is just 20.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
17.92%
Below 49%
Money owed to the company is 17.9% of assets, under the 49% limit.
Pass
Revenue purity
0.12%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
PTC clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 21%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-02. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PTC's ethical verdict changes
Today PTC passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 2 Nov 2026: it trades above our $142.63 fair value estimate, strong competitive moat.
Fair value range in USD, drawn from the 2026-11-02 screen. The gold marker is the market price at the same screen. The price runs 36.2% above the base estimate.
Third-party analyst targets: 15 covering, consensus Hold. The average target sits +6% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $142.63, with a range of $142.63 to $164.02, dated to the 2026-11-02 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 21.9x forward earnings, the price already runs ahead of the business. It trades 36% above our $142.63 fair value, so you would be buying at a premium, not a discount. The strong moat is real, but quality alone does not make an expensive price cheap.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PTC trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Markup$194.31-0.6%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it hold, with a mean price target of $201. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$195.54+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it hold, with a mean price target of $201. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$195.54+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it hold, with a mean price target of $201. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$195.54+0.4%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it hold, with a mean price target of $201. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$194.80-0.1%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it hold, with a mean price target of $201. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$194.97+1.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it hold, with a mean price target of $201. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$192.98+0.0%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it hold, with a mean price target of $201. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup$192.98+0.0%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it hold, with a mean price target of $201.
2026-10-18Markup$192.98+38.1%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 38.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it hold, with a mean price target of $201.
2026-10-11Markup · changed$139.69+0.0%Entry 7
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it hold, with a mean price target of $201.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
